Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (11-20 of 426) with videos related to

Pageof 43
Sort By:
European Urology Oncology|December 15, 2022
Concurrent Stereotactic Ablative Radiotherapy and Antiangiogenic Targeted Agents: Redefining the Therapeutic StrategyMimma Rizzo, Camillo Porta
The Lancet. Oncology|October 22, 2013
Axitinib dose titration: what's the limiting factor?Sebastiano Buti, Camillo Porta
Annals of Palliative Medicine|June 21, 2022
CheckMate 9ER patient-reported outcomes: the patient is not willing to give upMimma Rizzo, Camillo Porta
European Urology|October 10, 2012
Experience gathered from retrospective series on renal cell carcinoma is useful, but now it is time for a global claim for academically driven prospective studiesCamillo Porta, Chiara Paglino
Nature Reviews. Nephrology|April 18, 2019
Immune-based combination therapy for metastatic kidney cancerCamillo Porta, Mimma Rizzo
The Lancet. Oncology|August 21, 2019
Renal cell carcinoma treatment after first-line combinationsCamillo Porta, Manuela Schmidinger
Therapeutic Advances in Urology|April 18, 2018
Sunitinib in the treatment of renal cell carcinoma: an update on recent evidenceMimma Rizzo, Camillo Porta
World Journal of Hepatology|December 17, 2010
Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenibCamillo Porta, Chiara Paglino
Cancer Treatment Reviews|March 3, 2009
Tolerability of first-line therapy for metastatic renal cell carcinomaCamillo Porta, Cezary Szczylik
Annals of Translational Medicine|November 22, 2016
ASSURE <i>vs.</i> S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomicsCamillo Porta, Silvia Chiellino
Pageof 43

Showing results (11-20 of 426) with videos related to

Sort By:
Pageof 43
European Urology Oncology|December 15, 2022
Concurrent Stereotactic Ablative Radiotherapy and Antiangiogenic Targeted Agents: Redefining the Therapeutic StrategyMimma Rizzo, Camillo Porta
The Lancet. Oncology|October 22, 2013
Axitinib dose titration: what's the limiting factor?Sebastiano Buti, Camillo Porta
Annals of Palliative Medicine|June 21, 2022
CheckMate 9ER patient-reported outcomes: the patient is not willing to give upMimma Rizzo, Camillo Porta
European Urology|October 10, 2012
Experience gathered from retrospective series on renal cell carcinoma is useful, but now it is time for a global claim for academically driven prospective studiesCamillo Porta, Chiara Paglino
Nature Reviews. Nephrology|April 18, 2019
Immune-based combination therapy for metastatic kidney cancerCamillo Porta, Mimma Rizzo
The Lancet. Oncology|August 21, 2019
Renal cell carcinoma treatment after first-line combinationsCamillo Porta, Manuela Schmidinger
Therapeutic Advances in Urology|April 18, 2018
Sunitinib in the treatment of renal cell carcinoma: an update on recent evidenceMimma Rizzo, Camillo Porta
World Journal of Hepatology|December 17, 2010
Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenibCamillo Porta, Chiara Paglino
Cancer Treatment Reviews|March 3, 2009
Tolerability of first-line therapy for metastatic renal cell carcinomaCamillo Porta, Cezary Szczylik
Annals of Translational Medicine|November 22, 2016
ASSURE <i>vs.</i> S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomicsCamillo Porta, Silvia Chiellino
Pageof 43